The role of metabolites in biological functions other than in metabolism is likely to be considerably underappreciated given the technical difficulties of functionally characterizing these compounds. For instance, lipids are major components of membranes, but their role in morphogenesis is largely unknown 1,2 . A key technical problem is the inaccessibility of nontemplatederived compounds to specific in vivo targeting techniques such as gene knockouts or RNAi knockdowns that constitute the basis for the functional analysis of proteins. Although mass spectrometry (MS)-and NMR-based metabolomic approaches offer systems-level annotation and characterization of metabolites and their specific moieties, they cannot identify a causal relationship between a specific metabolite and its cellular function [3] [4] [5] . Imaging techniques are not yet of high spatial resolution (e.g., the emerging MS-based techniques); they lack molecular specificity or interfere with function (e.g., of lipids on membranes) 6 ; and the large panel of antibodies available for the detection of proteins does not exist for lipids. Here we co-opt the successful strategy of nucleic acid targeting to investigate non-nucleic acid-derived metabolites such as lipids.
IntroDuctIon
The role of metabolites in biological functions other than in metabolism is likely to be considerably underappreciated given the technical difficulties of functionally characterizing these compounds. For instance, lipids are major components of membranes, but their role in morphogenesis is largely unknown 1,2 . A key technical problem is the inaccessibility of nontemplatederived compounds to specific in vivo targeting techniques such as gene knockouts or RNAi knockdowns that constitute the basis for the functional analysis of proteins. Although mass spectrometry (MS)-and NMR-based metabolomic approaches offer systems-level annotation and characterization of metabolites and their specific moieties, they cannot identify a causal relationship between a specific metabolite and its cellular function [3] [4] [5] . Imaging techniques are not yet of high spatial resolution (e.g., the emerging MS-based techniques); they lack molecular specificity or interfere with function (e.g., of lipids on membranes) 6 ; and the large panel of antibodies available for the detection of proteins does not exist for lipids. Here we co-opt the successful strategy of nucleic acid targeting to investigate non-nucleic acid-derived metabolites such as lipids.
In a recent genome-wide RNAi tubulogenesis screen, we identified a number of lipid biosynthetic enzymes whose knockdowns generated the same specific polarity phenotype 7 . To find a putative common lipid compound through which these enzymes might act, we designed biosynthetic pathway screens and successfully identified ceramide glucosyltransferases (CGTs) as the endpoint biosynthetic enzymes, thereby revealing their single product glucosylceramide (GlcCer; the glycosphingolipid (GSL) backbone) as the common polarity-affecting lipid. Distinct biochemical functions of other identified enzymes, complemented by MS, characterized the compound being sought as a hydroxylated GlcCer (GlcCer-OH) with a C17-monomethyl branched-chain fatty acid (mmBCFA) and a saturated long-chain fatty acid (LCFA) of likely C22 length. No other existing technique could have identified this specific complex lipid's function by selectively removing it, nor would its biosynthetic enzymes have been identified in a forward mutagenesis/RNAi screen, as it required a double paralog knockdown. This analysis demonstrates that this biosynthetic pathway screen approach can be used to query, in an unbiased manner, the in vivo cell biological functions of non-DNA-encoded metabolites beyond their roles as biosynthetic substrates or metabolic products.
The approach consists of a stepwise, systematic, although not comprehensive targeting of all the molecules of the biosynthetic pathway of which the originally identified enzyme is a part. The same genetic/RNAi technique is used to search for a copy of the original phenotype with the goal of identifying the endpoint biosynthetic enzyme in the pathway, and thereby the underlying product species and perhaps the exact chemical characteristics of the compound. The approach (i) eliminates potential bias by starting the inquiry with the analysis of the function (phenotype) rather than the molecule of interest (a 'forward' rather than a 'reverse' molecular analysis), (ii) bypasses the problem of interconversion and compensation that creates a particular difficulty for the functional analysis of lipids 8, 9 and (iii) overcomes the obstacle that one enzyme synthesizes many products and affects different functions. This method can be used not only to functionally characterize metabolic products of biosynthetic genes that have already been identified in time-consuming genomewide RNAi screens (typically set aside as 'housekeeping' genes) but also to design 'lipid/metabolite' screens upfront by constructing RNAi libraries from their biosynthetic genes for the functional characterization of their products.
Strengths and limitations of this method's ability to identify the causative end product
The biosynthetic pathway screen approach relies on the copy of a signature phenotype that is generated by interference with one or several multiple biosynthetic enzymes in a linear pathway ( Figs. 1  and 2 ). The depletion of any intermediate (via its biosynthetic enzyme) in a specific pathway should (in principle) produce this phenotype, but inadvertently such screens also test conditions in which these same intermediates are increased, e.g., as accumulating substrates upstream of the catabolizing enzymes that are being tested via their depletion. Thus, seemingly paradoxically, the same phenotype may be present in animals that are depleted of a specific intermediate (by interference with its upstream biosynthetic enzyme) and in animals in which this same intermediate accumulates (secondary to interference with its downstream biosynthetic enzyme). However, in the latter scenario (accumulation of the intermediate), the phenotype is caused by the depletion of further downstream products, not by accumulation of this intermediate. This property of pathway screens, the simultaneous testing of intermediates as substrates and products, constitutes this approach's strength in uniquely addressing an inherent problem of metabolic analysis: the circularity of biosynthetic pathways and the possibility of compound interconnectivity ( Figs. 1 and 2 ; ref. 18 . It provides exceptionally strong evidence to demonstrate that it is the endpoint biosynthetic end product, not its upstream intermediates, that mediates the function under study. For instance, the same polarity defects were present in animals with loss and gain of ceramide (Cer) in our lipid biosynthetic pathway analysis (via depletion of Cer's upstream and downstream enzymes, respectively), suggesting that the mediating lipid compound sought was a further downstream product, not Cer itself (in this case GlcCer) 7 .
Although the biosynthetic pathway screen approach addresses the problem of interconversion, it may not always solve it, nor can it overcome the problem of biosynthesis compartmentalization to different subcellular membrane systems. For instance, only the additional absence of the phenotype in a null mutant of its catabolizing enzymes would unequivocally exclude the possible contribution of the next step metabolite to the function that is being examined. This becomes an obvious challenge in cases in which a non-endpoint intermediate is suspected to execute the function of interest, which is indicated, for instance, by the absence of phenotypes in animals that are depleted of all its downstream metabolizing enzymes. Such a scenario may require the construction of null mutants of all immediate downstream pathway components, which may consist of several enzymes, including their paralogs. Moreover, in this particular case, strict validation of the intermediate by compound rescue of the phenotype would require the construction of a double (multiple) mutant of the immediate upstream (synthesizing) and downstream (catabolizing) enzymes. It is therefore particularly difficult to characterize functions of pathway hub compounds, such as Cer, which is a substrate of three and a product of four different metabolic reactions in C. elegans, most of which are catalyzed by several paralogous enzymes (Fig. 2) . Finally, the compartmentalization of lipid biosynthesis to different endomembrane and plasma membrane domains may cause restrictions to these biochemical rules, the functional consequences of which cannot currently be predicted. However, none of these problems can be addressed at present by any other available in vivo technique. chemical characteristics. The direct identification of enzymes synthesizing complex lipids that are located further downstream in the pathway may make the broad screen (I) dispensible (see Supplementary Fig. 1 for complex lipid classes and their chemical compositions). The ancillary genetic and biochemical analyses serve to validate results, to connect results between different screen tiers and to exclude pathway branches, thereby reducing the number of enzymes that require screening.
Criteria for starting a biosynthetic pathway screen (prescreen confirmation and analysis: Steps 1-9) In principle, the identification of only one biosynthetic enzyme in a genetic/RNAi screen merits searching for the specific product that mediates its function. When the identified enzyme generates only one product, no further screening is necessary. More commonly, however, it generates multiple intermediates that require further analysis. The identification of more than one biosynthetic enzyme whose losses produce the same phenotype is particularly reassuring, and the identities of these enzymes may already be informative for the screen design. Biosynthetic pathway screens are particularly useful for the analysis of 'upstream' (in relation to their end product) biosynthetic enzymes that contribute to the generation of multiple products and thus reveal little information with regard to the identity of the product mediating the investigated function. In our polarity screen, the losses of four lipid biosynthetic enzymes were found to generate the same specific phenotype, which strongly suggested that they function through a shared lipid compound 7 . Three of them were common fatty acid (FA)-biosynthetic enzymes, one of which was the first enzyme for all FA biosynthesis (pod-2/acetyl-CoA carboxylase (ACC)), itself giving no clue as to the nature of this compound (Fig. 1) .
Several points should be checked before embarking on followon pathway screens (Fig. 3) . First, the specificity and robustness of the phenotype is essential for the analysis that relies on its tracking. Lethality or slow growth, for instance, may be induced by interference with any of various lipids and are thus not useful for tracking a single pathway; nor is a phenotype with low penetrance or expressivity. Second, enzyme knockdowns should be validated in a corresponding germline mutant that is expected to display the same or a related phenotype, particularly if only one enzyme was identified. Third, it is useful to exclude upfront the possibility that the phenotype results not from the loss of a product downstream of the missing enzyme but rather from the accumulation of a substrate upstream of the missing enzyme, a possible alternative cause (various lipid storage diseases, for instance, are caused by toxic substrate accumulation) 19 . The identification of more than one biosynthetic enzyme, or of first-step biosynthetic enzymes, may already suggest that their (common) loss-of-function phenotype is not caused by an accumulating substrate. This can be ascertained by rescuing the phenotype with exogenously supplemented lipids, provided that the identified enzyme synthesizes a product that can be substituted (an expected scenario, as pathway screens are likely to be used to analyze earlyacting, upstream biosynthetic enzymes that generate simple FAs). The biosynthesis of FAs  begins with a primer molecule, usually acetic acid, in the form of its CoA ester or attached to an acyl carrier protein (ACP), which forms malonyl-CoA by the activity of the enzyme acetyl-CoA carboxylase. Successive chain elongation, executed by adding malonyl-CoA as a chain extender to the single primer molecules through repeated multiple-step cycles catalyzed by the multifunctional FA synthase builds saturated short-chain FAs or medium-chain FAs. Acetyl-CoA is shown as a primer example for even-numbered straight-chain FAs, and isovaleryl-CoA is shown as an example for odd-numbered monomethyl branched-chain FAs (mmBCFAs). Middle left: long-chain FA (LCFA) biosynthesis. Straight and branched mediumchain FAs are further elongated in two-carbon units using malonyl-CoA as donor through repeated four-step (condensation, reduction, dehydration and reduction) cycles catalyzed by an enzyme complex with four distinct enzymes. mmBCFA biosynthesis uses specific enzymes for some reactions. In C. elegans, for instance, ELO-3 condenses straight-chain FAs and ELO-5 and ELO-6 condense branched-chain FAs, and LET-767 is used for the reduction of either. Middle right: biosynthesis of unsaturated FAs. Saturated FAs are desaturated to monounsaturated and polyunsaturated FAs (PUFAs) by a wide range of desaturase-(delta 5-, 6-, 9, 12 and omega-3) and PUFA elongase-(omega-3 and 6) activities to generate a variety of unsaturated FAs with different lengths and different numbers of double bonds. In contrast to higher plants and mammals, C. elegans possesses all of the enzymes that are required for the de novo biosynthesis of 20:4(n-6) and 20:5(n-3) FAs. Starting with the primer acetyl-CoA, the biosynthesis of the PUFA 20:5(n-3) by this route involves ~30 distinct enzymes and 70 reactions. Bottom: complex lipids. Products serve as building blocks for complex lipids, with saturated FAs dominating sphingolipids (SLs) and desaturated FAs dominating glycerols and phospholipids. Corresponding metabolic enzyme genes with experimentally confirmed functions in C. elegans are indicated in red.
Stearoyl-CoA (delta-9-) desaturase (fat-6,7 )
Acetyl-CoA carboxylase (pod-2 )
Acetyl-CoA Compound rescue simultaneously rules out the third, less likely cause of a phenotype: a dual-specific function of the enzyme that is unrelated to its biosynthetic product.
Broad initial pathway screening with a focus on simple metabolites: identifying the metabolite class (screen I: Steps 10-27) Lipid biosynthetic pathways can be divided into three parts that build on each other ( Fig. 1) : (i) short-and medium-chain FA biosynthesis (upstream; top); (ii) LCFA biosynthesis (middle); and (iii) complex lipid biosynthesis (downstream; bottom). Synthesis of both short-and medium-chain FAs and LCFAs involves fourstep elongation cycles (condensation, reduction, dehydration and reduction, depicted for LCFA synthesis), with malonyl-CoA, which is synthesized by ACC, as a chain extender. Medium-chain FAs and LCFAs can be further modified, for example, through desaturation by desaturases (right) and/or hydroxylation by hydroxylases (not shown). They then serve as precursors for complex lipids (bottom). Not infrequently, the loss of first step, often rate-limiting, biosynthetic enzymes generate detectable phenotypes, which implicate the entire field of possible downstream products as candidate mediating compounds. The first-tier follow-on pathway RNAi screen searching for phenocopy should assemble an RNAi library that targets genes involved in a wide range of lipid-related processes, including synthesis, transport and regulation, with an emphasis on the (upstream) basic machinery of FA metabolism (the size of libraries typically ranges from ~100 to 300 molecules, scalable depending on ease of phenotypic evaluation 7 ; Table 1 shows a collection of critical C. elegans FA biosynthetic enzymes). This analysis is targeted toward the identification of clues, and it should thus be broad rather than comprehensive.
Any positive hit will be both confirmatory with regard to the initially identified enzyme and newly informative with regard to further screen design. For example, the identification of an elongase in a first-level follow-on pathway screen for an initial identification of ACC/pod-2 ( Fig. 1) 
Confirming the involvement of a specific pathway branch (post-screen I confirmation and analysis: Steps 28-30)
It is not necessary to probe every enzyme of the pathway, but predictions can be tested for further confirmation: for example, our first-level follow-on lipid biosynthetic pathway screens identified two polarity-affecting enzymes that catalyze successive steps of FA elongation: the elongase ELO-3 and the 3-ketoacylCoA-reductase/KAR LET-767. Probing the enzyme catalyzing the reaction immediately downstream of KAR/LET-767 additionally identified the 3-hydroxyacyl-CoA dehydratase T15B7.2, thereby confirming pathway linearity ( Figs. 1 and 3 ; ref.
7).
Identifying the phenotype of interest in animals depleted of a first-step branch-specific enzyme will immediately direct followon screens to the corresponding branch. To increase confidence in the specific branch's involvement, findings can be validated by the analysis of the corresponding germline mutants and/or by rescuing the phenotype via a downstream lipid compound. As complex lipids-in contrast to FAs-may not be easily available for rescue, enzyme inhibitors can be used to evaluate whether they copy the phenotype of interest. Many small-molecule inhibitors have been developed to modify lipid biosynthetic enzyme activities [21] [22] [23] [24] [25] (Tables 1 and 2 ). For example, inhibitors of serine palmitoyltransferase include sphingofungins, lipoxamycin and myriocin. In C. elegans, they can generally be delivered by feeding. Inhibitors are often competitive substrates, and thus the same precautions apply for their supplementation as for lipid feeding (Steps 5-9). Their efficiency at inhibition in vivo varies; thus, although phenocopy will be confirmatory, a negative result will not rule out the targeted enzyme.
Taking advantage of intermediate modifications and pathway branchpoints (post-screen I confirmation and analysis: Steps 31 and 32)
Negative RNAi results, although informative, cannot by themselves exclude an enzyme as a pathway component. They could be caused by a number of reasons, including clone-or gene-specific RNAi resistance and redundancies, the latter being a typical scenario for biosynthetic enzyme genes, which often have paralogs (Tables 1 and 2 ). Although the screen design is guided by positive results, negative results can be used for branch exclusion (Fig. 3) .
In this case, further confirmation is necessary, with rigorous proof attainable only with germline null mutants; thus, it may require the construction of double, triple or even quadruple mutants. It is time-efficient to construct or obtain such mutants (many are already available) if, with their help, large numbers of compounds can be excluded. This will be the case if the identified enzymes operate upstream in the pathway, thereby contributing to the synthesis of multiple compounds. For instance, the exclusion of desaturation has the potential to rule out a large proportion of simple, as well as complex, lipids, inclusive of all glycerolipids and phospholipids (Fig. 1) . C. elegans contains three delta-9 desaturases, which are enzymes that carry out the first desaturation of 16:0 and 18:0 to 16:1n7 and 18:1n9 and thus generate monounsaturated FAs, with fat-5 encoding a palmitoyl-CoA desaturase and fat-6 and fat-7 encoding stearoyl-CoA desaturases (Fig. 1) . Therefore, if the fat-6(tm331); fat-5(tm420) fat-7(wa36) triple mutant, a severe loss-of-function mutant 13 , lacks the phenotype of interest, this will suggest that unsaturated FA-containing lipids do not mediate the function of the initially identified biosynthetic enzyme (although it will not, of course, exclude their function in other aspects of the same process). FAT-2, the only delta-12 desaturase in C. elegans, catalyzes the first reaction of polyunsaturated FA (PUFA) biosynthesis 10 . Lack of the phenotype of interest in the nonredundant strong loss-of-function allele fat-2(wa17), which was demonstrated to be completely devoid of normal PUFAs 13 , would exclude PUFA-containing lipids, for instance eicosanoids. In our study on polarity, we could exclude phosphoinositides-which were prime candidates given their well-described roles in polarity-on the basis of the absence of the polarity phenotype in fat-2(wa17) (ref. 7) . In principle, the same concept could be applied for any other type of compound modification (e.g., hydroxylation). Pathway branchpoints can furthermore be exploited in this way to exclude entire branches. The enzymes that catalyze the first committed (and ratelimiting) steps of sphingolipid (SL) and glycerolipid/glycerophospholipid biosynthesis (Fig. 2a,b) , respectively, are serine palmitoyltransferase and glycerol-3-phosphate acyltransferase or dihydroxyacetone phosphate acyltransferase. C. elegans contains three serine palmitoyltransferases (SPTL-1, 2 and 3) and three glycerol-3-phosphate acyltransferases (ACL-4, 5 and 6). The latter have been shown On the other hand, the depletion of several basic lipid biosynthetic enzymes and their products may generate only larval, rather than embryonic, lethality, and the fat-2(wa17) allele, although lacking all normal PUFAs, is viable 10 . In principle, any branchpoint that is further downstream in a biosynthetic pathway can be excluded in the same manner, although branchpoint exclusion may become difficult owing to the ability of many complex lipids to interconvert. For instance, the possibility of mutual interconversion of phosphatidylethanolamine and phosphatidylserine precludes using the phosphatidic acid-processing phospholipid biosynthetic enzymes phosphatidate phosphatase and cytidine diphosphate-diacylglycerol synthase for branch exclusion of specific phospholipids (Fig. 2) . Note that most phospholipids could also be excluded by definitively demonstrating that interrupting the first steps of unsaturated LCFA biosynthesis does not generate the phenotype (see above).
Demonstrating pathway contiguity: connecting simple and complex metabolites (post-screen I confirmation and analysis:
Step 33) Demonstrating contiguity between upstream and downstream (branch-specific) enzymes will confirm that the initially identified upstream enzymes exert their effects through this branch and are required for the synthesis of its products, while at the same time defining new functions for specific intermediates and delineating the biosynthetic pathway itself. For instance, our polarity screen revealed that mmBCFAs function in polarity, but it also demonstrated that they function as components of SLs 7 , which is a finding subsequently confirmed by Zhu et al. 28 .
Evidence for pathway contiguity can be accrued genetically and biochemically. Genetic interactions between hypomorphs, for instance, are expected to show enhancement, and the existence of such interactions would demonstrate that the enzymes operate in the same function but could not prove that they interact in the same pathway. Null mutants, which are necessary to address this question rigorously, may not be available given the early essential requirement of many biosynthetic steps. If aspects of the investigated function can be temporally or spatially separated, this can be used to demonstrate functional dependency of upstream on downstream components. Our reversible polarity phenotype, for instance, allowed the temporal separation of its induction and reversion: pathway contiguity could be definitively demonstrated by showing that reversion of a phenotype (induced by depletion of an upstream, FA-biosynthetic enzyme) required the branchspecific downstream enzyme (here, an SL-biosynthetic enzyme) 7 . Rescue of the phenotype by downstream lipid compounds is another definitive demonstration of pathway contiguity. However, whereas the supplementation of simple FAs generally suffices to rescue upstream enzyme losses, exogenous complex lipids may not fully replace the biological functions of their endogenous counterparts (constraints for rescue include, but are not limited to, uptake, species-specific compound composition and chirality, and spatial-subcellular-and temporal availability).
Finally, MS or other quantitative approaches can be used to demonstrate a concomitant relative decrease of the identified branch-specific enzyme's lipid products in animals depleted of their upstream FA biosynthetic enzymes. Given the possibility of interconnection and complementation between different lipid compounds, alterations of absolute levels of specific compounds must, however, be interpreted with caution.
In-depth screening of pathway branches with a focus on complex metabolites: identifying the metabolite species (screen II and post-screen II confirmation and analysis: Steps 34-58) Once a specific branch for complex lipid biosynthesis has been identified, it is possible to assemble a more comprehensive RNAi library for this specific branch, and to add (i) double and triple RNAi conditions to detect redundant enzymes and (ii) RNAisensitive conditions to detect mild effects (the size of libraries remains similar, although the number of targeted reactions is reduced; Table 2 shows a collection of C. elegans SL-biosynthetic enzymes with paralogs). Strong RNAi conditions can be achieved either by using RNAi-sensitive strains, such as eri-1(mg366), rrf-3(pk1426) or eri-1(mg366); lin-15B(n744), or by strengthening double-stranded RNA production by increasing the IPTG concentration in agar plates to induce the bacterial polymerase (see 'RNAi feeding plates' in Reagent Setup section). Given the abundance of paralogs (Tables 1 and 2) , the simultaneous perturbation of a redundant gene group using combinatorial RNAi is key. We identified the double knockdown of two CGTs as the endpoint biosynthetic enzymes in our study, and thereby GlcCer as the furthest downstream polarity-affecting lipid species 7 . A forward RNAi screen is unable to detect these genes, and a forward genetic screen is also unlikely to do so because of the high number of animals that would need to be screened to identify a double hit. The endpoint biosynthetic enzyme is validated, and its product is shown to mediate the function of the other identified biosynthetic enzymes through a combination of germline mutant analysis, specific inhibitors, MS analysis, genetic interaction experiments and/or exogenous compound rescue, as described above (pathway contiguity, Fig. 3 ). Definitive proof is rescue of the phenotype generated by loss of upstream biosynthetic enzymes via the endpoint product. This may not always be possible owing to specific requirements for complex lipids for certain functions (see above regarding pathway contiguity). For instance, C. elegans uses a C17 branched-chained long-chain base on its SLs, which is not readily available for purchase. If the above suggested experiments leave doubt, such compounds must either be purified from C. elegans or be chemically synthesized. Occasionally, bacteria that produce species-compatible lipids have been used for rescue. For example, a C17 iso-sphinganine has been isolated from Sphingobacterium spiritivorum to rescue worms that are deficient in serine palmitoyltransferases 28 , and mmBCFA-deficient worms can be maintained on Stenotrophomonas maltophilia 12 (these compounds are not present in OP50, the common C. elegans bacterial food source). Beyond demonstrating the absence (reduction) of the presumed lipid end product, MS analysis of wild-type versus mutant animals depleted of the endpoint biosynthetic enzyme (and/or of other enzymes whose losses produce the phenotype) will detect species-specific features of pathway products, the potential appearance of novel compounds, and it will contribute to the chemical characterization of the end product. Lipid extraction processes and MS instrument setup conditions differ for different lipids-e.g., for SLs, neutral glycerol lipids and glycerolphospholipids [29] [30] [31] [32] [33] [34] . The procedures that are outlined here are targeted to the analysis of C. elegans SLs, and specifically to complex SL species such as Cer, GlcCer and sphingomyelin.
Pathway screens for derivatives: identifying the specific compound (screen III: Steps 59-61)
Complex lipids themselves may be precursors for functionally distinct derivatives. For example, GlcCer, the end product identified in our polarity screen, provides the backbone for the large family of GSLs. A lipid glycosylation screen that is performed in conjunction with a prior lipid biosynthetic pathway screen may thus characterize the specific sugar modification of the identified lipid, and thereby the exact chemical composition of the compound. We used this approach, together with MS analysis, to identify the specific polarity affecting GSL in our study 7 . In this particular case, three negative results permitted the exclusion of a requirement for further sugar modifications of the identified lipid end product, thereby defining it as GlcCer itself: (i) the failure to identify the phenotype in the subsequent glycosylation RNAi screen; (ii) its absence in a presumed null mutant of beta4-mannosyltransferase, the first step sugar-biosynthetic enzyme for the arthro series of GlcCer derivatives; and (iii) the absence of lactosylceramide and consequently the entire GSL lacto series in C. elegans (demonstrated by MS analysis), restricting the C. elegans GSL repertoire to the arthro series. To further refine the structural characteristics of such an end product, additional chemical characteristics that may have emerged in the prior biosynthetic pathway screens via the requirement of modifying enzymes for the function under study can be confirmed by MS analysis. For instance, the requirement of an FA hydroxylase and of specific LCFA biosynthetic enzymes for polarity allowed us to characterize the endpoint polarity-affecting lipid compound as a hydroxylated GlcCer with a C17 branchedchain LCB and a LCFA with a length of likely C22 (ref. 7) .
MaterIals

REAGENTS
Lipid-related reagents
FAs of different lengths, numbers and positions of double bonds, hydroxyl groups and branches (Sigma, Matreya, Larodan, Nu-Chek Prep) Glycerolipids (mono-, di-and triglycerols; Sigma, Avanti Polar Lipids, Matreya, Larodan) Phospholipids with different headgroups, such as phosphocholine, phosphoethanolamine, phosphoserine, phosphoinosotol and phosphoglycerol (Avanti Polar Lipids, Matreya, Larodan) Sphingolipids with different sphingoid bases and lipid moieties (Sigma, Biomol, Avanti Polar Lipids, Matreya, Larodan) Lipid biosynthetic enzyme inhibitors: for examples of FA, glycerolipid and phospholipid biosynthetic enzyme inhibitors and references, see Table 1 , and for inhibitors of sphingolipid metabolic enzymes, see Table 3 . Use it directly for growing OP50 bacteria, and add 0.6-1 ml of 100 mg/ml ampicillin for growing RNAi bacteria. LB antibiotics plates Add 5 g of tryptone, 2.5 g of yeast extract, 5 g of NaCl and 7.5 g of agar per 1 liter of water and autoclave the mixture. Allow the medium to cool to 50-60 °C before adding 1 ml of 100 mg/ml ampicillin and 1 ml of 15 mg/ml tetracycline stock solutions. Pour the medium into plates, and leave them at room temperature (20-22 °C) until the agar sets. Store the plates at 4 °C for 2-3 months. Use them for growing RNAi bacteria. Nematode growth medium agar plates For 1 liter, add 3 g of NaCl, 2.5 g of peptone, 17 g of agar and 975 ml of H 2 O, and autoclave the mixture. Allow the medium to cool to 50-60 °C, and then add 1 ml of cholesterol (5 mg/ml in ethanol), 0.5 ml of 1 M CaCl 2 , 1 ml of 1 M MgSO 4 and 25 ml of 1 M potassium phosphate buffer, pH 6. Pour the medium into plates and leave them at room temperature until the agar sets. Store the plates at 4 °C for up to 1 month. Use the medium for growing worms. RNAi feeding plates For 1 liter, add 3 g of NaCl, 2.5 g of peptone, 17 g of agar and 975 ml of H 2 O and autoclave the mixture. Allow the medium to cool to 50-60 °C, and then add 1 ml of cholesterol (5 mg/ml in ethanol), 1 ml of 1 M CaCl 2 , 1 ml of 1 M MgSO 4 , 25 ml of 1 M potassium phosphate buffer, pH 6, 2.4 ml of 200 mg/ml IPTG (final concentration: 2 mM) and 0.5 ml of 50 mg/ml carbenicillin (final concentration: 25 µg/ml). Pour the medium into plates and leave them at room temperature until the agar sets. Make plates fresh 1-3 d before using for RNAi knockdown by feeding. Different IPTG concentrations will produce milder or stronger RNAi effects, and the appropriate concentration should be empirically determined for the phenotype under study. M9 buffer Dissolve 3 g of KH2PO 4 , 6 g of Na 2 HPO 4 and 5 g of NaCl in 1 liter of water, and autoclave the mixture. Add 1 ml of 1 M MgSO 4 after cooling the buffer to room temperature. Use the buffer for washing and aliquotting worms. This solution may be stored at room temperature for months. Bleach solution Add 25 ml of 10 N NaOH, 15 ml of household sodium hypochlorite solution and 60 ml of water to make a 100-ml solution. Bleach solutions lose activity over time. Freshly prepare the solution before using it for synchronizing worms. CaCl 2 , 1 M Add 147.01 g of CaCl 2 to 500 ml of deionized water and stir it until CaCl 2 is completely dissolved, and then bring the volume to 1 liter using deionized water, and autoclave the mixture. Allow the solution to cool to room temperature. This solution may be stored indefinitely at room temperature. MgSO 4 , 1 M Add 246.48 g of MgSO 4 to 500 ml of deionized water, and stir it until MgSO 4 is completely dissolved, and then bring the volume to 1 liter using deionized water, and autoclave the mixture. Allow the solution to cool to room temperature. This solution may be stored indefinitely at room temperature. Potassium phosphate buffer, 1 M (pH 6.0) Add 30.1 g of K 2 HPO 4 and 118.1 g of KH 2 PO 4 to 500 ml of deionized water, stir it until K 2 HPO 4 and KH 2 PO 4 are completely dissolved, and then bring the volume to 1 liter using deionized water and autoclave the mixture. Allow the solution to cool to room temperature. This solution may be stored indefinitely at room temperature. NaOH, 10 N Add 20 g of NaOH to 50 ml of deionized water, and stir it until NaOH is completely dissolved. This solution may be stored indefinitely at room temperature and in plastic containers. Ampicillin stock solution (100 mg/ml) Add 1 g of ampicillin to 10 ml of deionized water to make stock solution. Sterilize the stock solution by filtering with a 0.22-µm filter, and store it in 1-ml aliquots in 1.5-ml tubes at −20 °C for 6-12 months. Carbenicillin stock solution (50 mg/ml) Add 500 mg of carbenicillin to 10 ml of deionized water to make stock solution. Sterilize the stock solution by filtering with a 0.22-µm filter, and store 1-ml aliquots in 1.5-ml tubes at −20 °C for 6-12 months. Tetracycline stock solution (15 mg/ml) Add 150 mg of tetracycline to 10 ml of ethanol to make stock solution. Sterilize the stock solution by filtering with a 0.22-µm filter, and store 1-ml aliquots in 1.5-ml tubes at −20 °C for 6-12 months. IPTG stock solution (200 mg/ml) Add 2 g of IPTG to 10 ml of deionized water to make stock solution. Sterilize the stock solution by filtering with a 0.22-µm filter, and store 1-ml aliquots in 1.5-ml tubes at −20 °C for 6-12 months. proceDure prescreen confirmation and analysis: validation of the phenotype in germline mutants • tIMInG 1 d to 3 weeks 1| To cross the strain of the initial RNAi screen (a strain typically carrying a marker, e.g., a GFP label-used as example here) into the germline mutant strain under study, mate N2 male worms into the marker strain (could also generate a male stock of this strain).
EQUIPMENT SETUP HPLC elution protocol
2|
Cross the resultant GFP + male worms into hermaphrodites of the mutant (a/a) to generate gfp/+; a/+ (if gfp is integrated into the genome) or a/+; gfp (if gfp is transmitted on an extrachromosomal array) F 1 progeny and allow to self.
3|
Clone the GFP + F 2 progeny to isolate homozygous GFP + mutants (expected frequency: 1/12 if the GFP reporter is integrated and 1/4 if on an extrachromosomal array).
4|
Evaluate whether the homozygous mutants display the same or similar phenotype as the corresponding RNAi animals (see http://www.wormbook.org for standard genetic procedures).  crItIcal step Depending on the phenotype, high-resolution microscopic analysis (e.g., differential interference contrast and/or confocal microscopic analysis) might be needed, in addition to phenotypic screening using a dissecting microscope.
prescreen confirmation and analysis: exclusion of lipid substrate toxicity or lipid-unrelated mechanisms • tIMInG 2-7 d 5| Prepare lipid stock solution (see Reagent Setup).
? troublesHootInG 6| Mix lipid stock solution or solvent control with either OP50 or gene-specific HT115 RNAi bacteria (e.g., 5-40 µl + 120 µl, respectively, for each six-well plate; see
Step 24, RNAi screen setup). The concentration required for rescue needs to be titrated for each compound or compound mixture.  crItIcal step Some solvents interfere with RNAi and may therefore produce the false impression of phenotype rescue; it is therefore important that these experiments be run with the appropriate solvent controls (and/or that results be confirmed in germline mutants).
? troublesHootInG 7| Seed the mixture of lipid/solvent and bacteria onto the RNAi or nematode growth medium (NGM) plates, and allow the bacteria to grow for 6-8 h.  crItIcal step Most lipids are not soluble in aqueous medium, and thus they are not well distributed when they are directly applied to a bacterial lawn on NGM plates (some extent of precipitation of the lipid compounds might occur). The Watts lab has described an alternative method in which feeding plates containing lipids are made by mixing the lipids into the agar in the presence of tergitol, a nonionic surfactant 35 . ? troublesHootInG 8| Seed or pick worms onto the lipid-supplemented NGM or RNAi plates. ? troublesHootInG 9| Score the phenotype. ? troublesHootInG screen I: broad biosynthetic pathway rnai screen: assembly of an rnai feeding library • tIMInG 3 d-1 week (depending on familiarity with metabolic pathways) 10| Expanding from the specific biosynthetic enzyme that was identified, assemble the initial library with the aim to target genes/transcripts involved in a wide range of lipid-related processes and with the emphasis on the basic machinery of FA metabolism. Taking advantage of the high structural conservation of biosynthetic enzymes throughout phylogeny, use several or all of the following approaches to assemble the library:
Step 10A, assembly of a list of C. elegans lipid metabolism-related genes/proteins; Step 10B, assembly of a list of lipid metabolism-related genes/proteins of all species;
22| Incubate the plates at 20 °C for 36-48 h.
23|
Wash the worms off the plates using M9 buffer three times before pipetting onto RNAi feeding plates for screening (for plate preparation, see
Step 26).
screen I: broad biosynthetic pathway rnai screen: rnai feeding setup and phenotype scoring • tIMInG 3-6 d 24| The day before setting up RNAi feeding experiments, inoculate bacteria from Step 12 into 500-800 µl (50-200 µl final volume is required for each individual feeding experiment, depending on the type of plate used: 6-, 24-or 96 well) of LB medium plus 100 mg/ml ampicillin in a 96-deep well plate, and allow them to grow overnight in a shaking incubator at 220 r.p.m. at 37 °C.  crItIcal step It is important to use freshly grown bacteria to achieve the full RNAi effect.
25|
The following morning, induce transcription of double-stranded RNA by adding 50-200 µl of the bacterial cultures from
Step 24 to each RNAi plate per well (containing IPTG, see 'RNAi feeding plates' in Reagent Setup section). For knockdowns of multiple genes, add an equal volume of each bacterial feeding clone to the plates.  crItIcal step RNAi has an intrinsic variability; therefore, it is essential to set up replicates for every clone.
In each experimental run, at least one positive and one negative control are included (Step 27).
26| After 10-12 h, for parentally induced RNAi (where the F 1 generation is scored), pipette L3-L4 worms from
Step 23 onto each RNAi well per plate (typically 5-10 worms in a volume of 10 µl of M9 buffer for six-well plates); for RNAi induced in the same generation, pipette eggs or L1s from
Step 20 (typically 50-100 worms in a volume of 10-20 µl of M9 buffer for six-well plates).  crItIcal step Experiments may need to be repeated with larger number of worms if the brood size is low.
27|
Scoring depends on the screen setup and the nature of the phenotype of interest. To score morphological F 1 phenotypes on a dissecting microscope, day 2 is optimal for scoring embryonic phenotypes, and day 3 is optimal for scoring larval phenotypes. If maternal effects are being scored, also inspect the F 3 generation. Suitable bacterial control RNAi clones should be included for each set of RNAi experiments. The optimal positive control is a clone that copies the phenotype of interest, and the optimal negative control is a clone that produces an unrelated phenotype or no detectable phenotype (e.g., targets a non-C. elegans gene). (ii) Seed the mixture of solution onto the NGM plates and let OP50 bacteria grow for 6-8 h (see 'NGM agar plates' in Reagent Setup section)  crItIcal step Some precipitation may occur owing to water insolubility (see Steps 5-9, analysis of lipid compounds, for caveats with regard to lipophilic substances). (iii) Seed eggs, larvae or adults of the strain used to carry out the initial screen onto the plates. (iv) Score the phenotype.
? troublesHootInG (c) rescue of phenotype via downstream lipid product(s).
(i) Use procedures described in Steps 5-9 to rescue the branch-specific enzyme defect with downstream lipids.  crItIcal step This approach may not be an option, as only complex lipids (rather than FAs) will rescue branch-specific enzyme knockdowns-which may require species-specific compounds that are not readily identified or available (see Experimental design). Failure of rescue with complex lipids must thus be interpreted with caution.
confirmation and analysis of results of screen I: exclusion of lipid classes or branches • tIMInG 1-4 weeks (depending on the availability of mutants and their characterization); this is optional if a branch-specific enzyme was identified, but required in the absence of such a positive result 31| Generate severe double or triple loss-of-function conditions for paralogous enzymes (ideally null mutants) to abolish enzymatic reactions for the purpose of pathway branch exclusions, using a combination of standard genetic procedures, RNAi and specific enzyme inhibitors (see Steps 1-4 for an example of a simple cross; Steps 13-27 for RNAi;
Step 30B for treatment with inhibitors; and http://www.wormbook.org for standard genetic procedures, including the introduction of genetic balancers into lethal mutants). Some double and triple mutants are already available at http://www.cbs.umn.edu/CGC/ or they may have been generated for specific studies (e.g.
, fat-6(tm331); fat-7(wa36). fat-7(wa36) fat-5(tm420). fat-6(tm331); fat-5(tm420). acl-4(xh10) acl-5(xh9). cgt-3(tm504); +/DnT1; cgt-1(qa1809)/DnT1; cgt-2(tm1097). cgt-3(tm504); +/DnT1
; cgt-1(qa1809)/DnT1; cgt-2(tm1192) double and triple mutants 13, 26, 27 ; Fig. 1 ).
32|
Examine the mutant for copies of the phenotype.  crItIcal step To definitively exclude a class or branch, MS analysis is additionally required to demonstrate the absence of the product of the enzymatic reaction in question: see Steps 37-58 below for MS analysis (such data may, however, be already available for some of these mutants).  crItIcal step Consider on a case-by-case basis whether it is worth investing time into genetic interaction experiments, as haploinsufficiency, as well as dosage-dependent nonallelic noncomplementation, is thought to occur only rarely in C. elegans 36 . We did, however, find them helpful when examining metabolic enzymes and dosage-dependent processes, and we have also used heterozygous germline mutants for this purpose 7 .
? troublesHootInG (b) phenotype rescue via downstream branch product(s) (i) Refer to Step 30C (including caveats), and use the procedures described in Steps 5-9 to rescue an upstream biosynthetic enzyme defect with a downstream branch-specific lipid. Step 36A, scoring for phenocopy in the corresponding germline mutant;
Step 36B, scoring for phenocopy by the specific inhibitor of the identified enzyme;
Step 36C, screening for genetic interaction of the identified enzyme with any or all other enzymes of the pathway;
Step 36D, rescue of the loss-of-function phenotype(s) of the endpoint biosynthetic enzyme and/or of any upstream enzymes by the presumed lipid end product; and
Step 36E, MS analysis of the loss-of-function mutant/RNAi animal(s) that display the phenotype to demonstrate the absence (reduction) of the presumed lipid end product. Set up 150-mm RNAi (for RNAi depletion) or NGM culture plates (for germline mutants) to grow a sufficiently large amount of worms for lipid extraction, aiming for a final worm pellet of at least 200 µl. If L1 larvae are to be analyzed (a likely scenario given the frequent L1 lethality of lipid biosynthetic enzyme mutants/RNAi animals), 600-800 such plates may be required. As controls, set up equal amounts of synchronized wild-type L1 larvae, which are grown on the same bacterial strain (E. coli HT115).
38|
Collect worms by rinsing the RNAi plates with M9 buffer and then letting the worms sediment at 4 °C.
39|
Subject worm pellets to three cycles of freezing in liquid nitrogen for 30-60 min and by thawing on ice for 30 min, followed by sonication (10 s each time, 3-5 times for each cycle).
40|
Combine samples with the same genotype into one tube, lyophilize the worm suspension using a freeze-dryer and measure dry weight using an analytical balance.
41|
Add methanol, chloroform and water in a 2:1:1 ratio (e.g. 2/1/1 ml) to each sample (~40-60 mg of dried worm pellet).
42|
Spike 100 µl of internal standard mixture (e.g., a SL standard mixture).
43|
Mix by vortexing for 5 min to achieve a single-phase cloudy solution.
44|
Incubate the samples at 48 °C overnight in a heating block.
45| Add 1.0 ml of 1 M KOH into each sample after cooling to room temperature.
46|
Sonicate the samples in a bath sonicator for 5 min.
47| Incubate them at 37 °C for 2 h.
48|
Remove a 1-ml aliquot of the extract and dry it under vacuum for long-chain base analysis when necessary.
49|
Add 600 µl of glacial acetic acid to neutralize the remaining solution.
50| Add 4 ml of water and 2 ml of chloroform, and shake the samples for 2 min.
51|
Centrifuge at 1,000g for 10 min at 20 °C and discard the upper layer.
52|
Collect the lower layer for analysis, and reduce the volume to ~100 µl using a CentriVap Benchtop Vacuum Concentrator.  pause poInt The samples can be stored at -20 °C for 2-3 months.
53|
Reconstitute the samples to a final volume of 1.0 ml with a 9:1 mixture of HPLC mobile phases A and B (see Reagent Setup section).  crItIcal step Glassware rather than plastic should be used for all extraction procedure steps that use organic solvents, in order to avoid extracting molecules from the plastic that could interfere with the biochemical analysis of lipids.
54| LC-MS. Carry out HPLC using Dionex U3000 liquid chromatograph equipped with an Astec NH2 column (4.5 mm × 150 mm, 5-µm particles); mobile phases A and B are prepared as described in Reagent Setup section, and elution protocol is described in Equipment Setup section. 56| Inject 5 µl of each 1-ml extract from Step 53.
57|
Calculate concentrations for each compound from the response ratio of compound area/internal standard area of the corresponding period per dry weight of the sample.
58|
Compare the lipid composition of mutant/RNAi animals with control animals.  crItIcal step It is not always useful to generate whole lipidomic profiles, as this may decrease the sensitivity for a lipid species of interest.
screen III: metabolic pathway rnai screen for derivatives (optional): assembly of an rnai feeding library • tIMInG 3-7 d 59| Construct an RNAi library from enzymes known or expected to biochemically modify the identified lipid end product-for example, enzymes functioning in lipid glycosylation (for library assembly see Steps 10-12). As described in
Step 34 (and library size permitting), aim for concomittant depletion of paralogs and a broad range of depletion conditions. screen III: metabolic pathway rnai screen for derivatives (optional): rnai screen procedure • tIMInG 6-12 d 60| Synchronize worms, set up RNAi feeding experiments and score phenotypes, as described for screen I (Steps 13-27). ? troublesHootInG Troubleshooting advice can be found in table 4. The range of effective doses of inhibitor is narrow (no effect with lower, and early lethality with higher, dose)
The inhibitor has weak potency and lacks specificity Can attempt to carefully titrate inhibitor concentration; check the ability of the inhibitor to enhance the (mild) loss of the corresponding biosynthetic enzyme In the version of this article initially published, the text detailing the HPLC elution protocol in the Equipment Setup section (a 2-min column pre-equilibration in 9:1 A:B (vol/vol); sample injection; 2-min wash with 100% A; 14-min linear gradient to 100% B; and 15-min post-run column equilibration) was incorrect and has been changed to read: a 2-min column preequilibration in 9:1 A:B (vol/vol); sample injection; 2-min wash with 100% A; 12-min linear gradient to 100% B; and 1-min post-run column equilibration. The error has been corrected in the HTML and PDF versions of the article.
